Showing 6641-6650 of 7460 results for "".
- Gene Expressions May Be Key to More Youthful Looking Skinhttps://practicaldermatology.com/news/gene-expressions-may-be-key-to-more-youthful-looking-skin/2457962/Some individuals’ skin appears more youthful than their chronologic age, and now new research indicates that increased expression of certain genes may be the key to intrinsically younger looking — and younger behaving — skin. The findings appear in the
- Milestone Scientific Set To Launch New Botox Delivery Instrumenthttps://practicaldermatology.com/news/milestone-scientific-set-to-launch-new-botox-delivery-instrument/2457965/Botulinum toxin injections may be about to get smarter and more comfortable as Milestone Scientific Inc. gears up to launch its novel and proprietary cosmetic injection instrument. The new cosmetic injection instrument allows the clinician
- Water Baths As Effective As Bleach Baths for Eczemahttps://practicaldermatology.com/news/water-baths-as-effective-as-bleach-baths-for-eczema/2457967/Water baths are as good as bleach baths for treating eczema, and they are safer, finds a new Northwestern Medicine study. Bleach baths can cause stinging and burning of skin, and occasionally even trigger asthma flare-ups in patients. “I don’t know if it throws the bab
- Psoriasis Severity Linked to Diabetes Riskhttps://practicaldermatology.com/news/psoriasis-severity-linked-to-diabetes-risk/2457970/Psoriasis patients are more likely to develop Type 2 diabetes than their psoriasis-free counterparts, and this risk increases dramatically based on the severity of the disease, according to researchers from the Perelman School of Medicine at the University of
- Sonoma Pharmaceuticals Launches Loyonhttps://practicaldermatology.com/news/sonoma-pharmaceuticals-launches-loyon/2457971/Sonoma Pharmaceuticals, Inc. has begun US commercialization of the company’s new Loyon® product. Under the supervision of a healthcare practitioner, Loyon is intended to manage and relieve the scaling, erythema, and itching associated with various types of dermatoses including seborrhea
- Obagi Eyes the Future Under New Ownershiphttps://practicaldermatology.com/news/obagi-eyes-the-future-under-new-ownership/2457973/The sale of Obagi Medical Products to the Haitong International Zhonghua Finance Acquisition Fund I, L.P. and limited partners China Regenerative Medicine International (CRMI) Ltd. is now complete. The new
- Promius Pharma Employees Fundraise for Hurricane Victimshttps://practicaldermatology.com/news/promius-pharma-employees-fundraise-for-hurricane-victims/2457974/Promius Pharma LLC's employees raised $12,715 to support American Red Cross relief efforts to assist those affected by the recent hurricanes. Additionally, Promius' parent company Dr. Reddy's Laboratories matched this donation for a combined contribution
- Isdin Introduces Two New Productshttps://practicaldermatology.com/news/isdin-introduces-two-new-products/2457977/ISDIN is rolling out ISDIN Age Contour plus a new shade in their ISDINCEUTICS Skin Drops collection. ISDIN AGE CONTOUR is a triple-action face and neck cream that aims to reduce jawline sagging and glycation in the skin as well as protect&nb
- NRS Introduces New Standard Classification and Pathophysiology of Rosaceahttps://practicaldermatology.com/news/nrs-introduces-new-standard-classification-and-pathophysiology-of-rosacea/2457979/The National Rosacea Society (NRS) is introducing a new standard classification and pathophysiology of rosacea. The updated system appears in the Journal of the American Academy of Dermatology. Devel
- Long-Term Use of Lilly's Taltz Shows Efficacy Improvements in PsA for Patients with Prior Inadequate Response or Intolerance to TNF Inhibitorshttps://practicaldermatology.com/news/long-term-use-of-lillys-taltz-shows-efficacy-improvements-in-psa-for-patients-with-prior-inadequate-response-or-intolerance-to-tnf-inhibitors/2457980/Patients with active psoriatic arthritis (PsA) treated with Taltz (ixekizumab), who were previously intolerant or had inadequate responses to TNF inhibitors, showed improvements in the signs and symptoms of PsA across treatment groups for up to 52 weeks, according to Eli Lilly and Company. Interi